The purpose of this piece is not to defend the Planning Commission on poverty figures but to indicate that the methodologies have evolved over time after considerable research and they are useful for policy purposes if not for linking with entitlement programmes (some of us have written earlier that the poor and vulnerable are more numerous than the commission's poverty figures and these should be delinked from entitlement programmes).  The commission...

The State government of the day spares no occasion to make a mention of the “shambles” the 34 years of Left rule has left West Bengal in. The Economic Review presented in the State Legislative Assembly, however, tells a different story. It highlights several areas where the State's performance has been “impressive over the last few years”. Mention is made of progress in agriculture, industry, rural development, industrial relations and rising...

-The Telegraph The economic survey has challenged an international assessment that has ranked India 125, or near-bottom, among 132 countries on environmental performance, but has acknowledged that air pollution has increased to alarming levels. The survey, released by the Union government today, has questioned the methodology of the Environmental Performance Index 2012 that has assigned air quality in India a rank of 132, the worst in the world, and similarly low ranks...

India will be one of the youngest nations by 2020 and this changing demographic condition, while providing great opportunities, could pose some challenges too, the Economic Survey 2011-12 has said. India is passing through a phase of unprecedented demographic changes, wherein the proportion of the working age population (15-59 years) is likely to rise from around 58 per cent in 2001 to over 64 per cent by 2021, according to the...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...